Nurix Therapeutics Inc. has a Beta (Market Risk) of 1.5167, indicating a somewhat significant risk compared to the market. To understand what this beta means for Nurix, consider that as the market rises, the company is projected to outperform it. Conversely, if the market yields negative returns, Nurix Therapeutics Inc. is likely to underperform.
While it's crucial to monitor Nurix Therapeutics Inc.'s price patterns, one should exercise caution when using equity's historical price patterns. Our approach to predicting any stock's future performance involves examining both its past performance charts and the overall business, including all available technical indicators.
Nurix Therapeutics Inc. offers twenty-one different technical indicators that can assist in evaluating its performance. The company has an expected return of -0.37%. It's essential to verify Nurix Therapeutics Inc.'s information ratio and downside variance to determine if its past performance will be replicated at some point in the near future.
Detailed examination of Nurix Stock
Nurix Therapeutics Inc (NRIX) has been experiencing a downtrend, which could be attributed to its weak forward indicators. The company's EPS estimate for the next year is projected to be a loss of
3.39, which is higher than the current year's estimated loss of 3.04. This suggests that the company's
financial health may deteriorate further. Additionally, the company has a high probability of bankruptcy at
24.37%, which is a risk factor for potential investors. The company's return on assets and return on equity are both negative, at -0.28 and -0.62 respectively, indicating that the company is not generating profits from its assets or equity. Furthermore, the company's total operating expenses of
222.5M are significantly higher than its revenue of 38.63M, which could be a contributing factor to its negative net income from continuing operations of
180.4M.
Typically, a company's
financial statements are the reports that show the
financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Nurix TherapeuticsInc income statement, its balance sheet, and the statement of cash flows. Potential Nurix TherapeuticsInc investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Nurix TherapeuticsInc investors may use each financial statement separately, they are all related. The changes in Nurix TherapeuticsInc's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Nurix TherapeuticsInc's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our
technical analysis and
fundamental analysis pages.
The goal of Nurix TherapeuticsInc
fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Nurix TherapeuticsInc performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Nurix TherapeuticsInc shares is the value that is considered the true value of the share. If
the intrinsic value of Nurix is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Nurix TherapeuticsInc. Please read more on our
fundamental analysis page.
How effective is Nurix TherapeuticsInc in utilizing its assets?
Nurix TherapeuticsInc reports assets on its Balance Sheet. It represents the amount of Nurix resources that either has an existing economic value or will provide some form of benefits in the future. By effectively utilizing its assets, Nurix TherapeuticsInc aims to generate revenue, control costs, drive operational efficiency, and enhance profitability. Optimizing asset utilization helps maximize shareholder value and maintain a competitive position in the Biotechnology space. To get a better handle on how balance sheet or income statements item affect Nurix volatility, please check the breakdown of all its
fundamentals.
Are Nurix TherapeuticsInc Earnings Expected to grow?
The
future earnings power of Nurix TherapeuticsInc involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Nurix TherapeuticsInc factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Nurix TherapeuticsInc
stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Nurix
expected earnings.
Nurix TherapeuticsInc Gross Profit
Nurix TherapeuticsInc Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Nurix TherapeuticsInc previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Nurix TherapeuticsInc Gross Profit growth over the last 10 years. Please check Nurix TherapeuticsInc's
gross profit and other
fundamental indicators for more details.
Breaking down the case for Nurix TherapeuticsInc
Many companies such as Nurix TherapeuticsInc have both institutions investors and insiders sharing the ownership. Retail investors typically buy and sell stocks in round lots of 100 shares or more. Other other hand institutional investors are known to buy and sell in block trades of 10,000 shares or more. Let's take a look at how the ownership of Nurix is distributed among investors.
Ownership Allocation
Nurix TherapeuticsInc maintains a total of fourty-seven million four hundred fourty-five thousand four hundred
outstanding shares. The majority of Nurix TherapeuticsInc
outstanding shares are owned by
institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Nurix TherapeuticsInc to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Nurix TherapeuticsInc. Please pay attention to any change in the institutional holdings of Nurix TherapeuticsInc as this could imply that something significant has changed or about to change at the company. Please note that no matter how much assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
| Retail Investors | 0.58 |
| Insiders | 3.48 |
| Institutions | 95.94 |
Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Nurix TherapeuticsInc has an asset utilization ratio of 9.27 percent. This suggests that the company is making $0.0927 for each dollar of assets. An increasing asset utilization means that Nurix TherapeuticsInc is more efficient with each dollar of assets it utilizes for everyday operations.
| Current Assets309.5 M | Assets Non Current102.5 M | |
| Current Assets | 309.46 Million | 75.09 |
| Assets Non Current | 102.5 Million | 24.87 |
| Tax Assets | 188,432 | 0.0457 |
Nurix Therapeutics Inc (NRIX) is currently experiencing a downtrend in the market, which may be attributed to its weak forward indicators. The biotechnology company reported a significant loss of
$180.4M in net income applicable to common shares, with a negative earnings per share (EPS) of $3.49, significantly higher than the estimated EPS of -$3.04 for the current year. This is despite a total revenue of $38.6M, suggesting high operating expenses totalling
$222.5M. The company's total assets stand at $416.8M with total current liabilities of $70.7M. This indicates a net working capital of $247.8M, providing some financial stability. However, the probability of bankruptcy is moderately high at 24.37%, which could be a contributing factor to the stock's current downtrend. Moreover, the company's market capitalization stands at $455.95M, while its
enterprise value.is significantly lower at $205.1M. This discrepancy may be a reflection of the market's perception of the company's
future profitability, which aligns with the negative forward indicators. Finally, the company's price to book ratio of 1.70X suggests that the stock may be undervalued, potentially offering opportunities for investors willing to take on the associated risks.
Some Nurix technical indicators suggest collapse
Nurix Therapeutics Inc.'s stock is exhibiting certain technical indicators that may hint at a potential decline. One such indicator is the semi-variance, a statistical tool utilized to gauge the potential volatility of a stock's returns. Recently, the semi-variance has dipped to 20.33, which could suggest an impending volatility decrease. This drop in semi-variance may imply that the stock's price fluctuations are becoming less extreme, signaling a potential downtrend. Investors are advised to exercise caution and monitor the stock closely for further signs of a potential downfall. Nurix Therapeutics Inc. exhibits an above-average semi-deviation for the current time horizon. We recommend investors to investigate Nurix Therapeutics Inc. individually to ensure that intended
market timing strategies and available technical indicators are consistent with their estimates about the future
systematic risk of Nurix Therapeutics Inc. Understanding different
market volatility trends often aids investors in timing the market.
Proper utilization of volatility indicators enables traders to measure Nurix Therapeutics Inc.'s stock risk against market volatility during both bullish and bearish trends. The elevated level of volatility that accompanies bear markets can directly impact Nurix Therapeutics Inc.'s stock price, adding stress to investors as they witness their shares' value decrease. This typically compels investors to rebalance their portfolios by purchasing different stocks as prices drop. In conclusion, the overall
analyst consensus for Nurix TherapeuticsInc is a 'Buy', with a total of
8 Strong Buys, 2 Buys, and only 1 Hold. The highest estimated target price stands at
$53, significantly higher than the current market value of $10.08. The real value of the stock is estimated at $14.73, indicating a potential upside. However, investors should also consider the possible downside price of $6.09. Given the fiscal year end in November, the company's performance and
future prospects should be closely monitored. Based on these data points, Nurix TherapeuticsInc presents a potentially lucrative investment opportunity, but with a degree of risk that investors should be aware of. .
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Nurix TherapeuticsInc. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com